Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 3/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.40 |
| ▸ | F3 | P13726 | 3/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TOP1 | P11387 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18805297 | 1.00 | PRKAG1 (0.40) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL24503392 | 1.00 | PRKAG1 (0.40) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL18805188 | 0.98 | PRKAG1 (0.38) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL23685930 | 0.97 | PRKAG1 (0.38) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL24859162 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL21980463 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL23686027 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL23028864 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL23685906 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 | |
| SCHEMBL23633959 | 0.97 | PRKAG1 (0.39) | PRKAG1PRKAA2PRKAB1F3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | claimed |
| CN-117750886-A | Salt-containing beverage with improved taste | 可口可乐公司 | 2024-03-22 | — | — | CN | claimed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | claimed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | claimed |
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | THE COCA COLA CO (US) | 2026-05-14 | — | — | US | disclosed |
| US-12557831-B2 | Mogrosides and uses of the same | THE COCA-COLA COMPANY (US) | 2026-02-24 | — | — | US | disclosed |
| US-12495818-B2 | Dihydrochalcones from Balanophora harlandii | THE COCA-COLA COMPANY (US) | 2025-12-16 | — | — | US | disclosed |
| US-12428662-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4608168-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | The Coca-Cola Company (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-3614860-B1 | SWEETNESS AND TASTE IMPROVEMENT OF STEVIOL GLYCOSIDE AND MOGROSIDE SWEETENERS WITH DIHYDROCHALCONES | COCA COLA CO (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12338476-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-06-24 | — | — | US | disclosed |
| US-12286661-B2 | Methods for making high intensity sweeteners | FIRMENICH INCORPORATED (US) | 2025-04-29 | — | — | US | disclosed |
| CN-115666265-A | Beverage with enhanced flavor comprising siamenoside I | 可口可乐公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115484828-A | Fat-free non-dairy cream composition | 可口可乐公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220287346-A1 | STABLE CREATINE BEVERAGES | THE COCA-COLA COMPANY | 2022-09-15 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114630587-A | Stabilized creatine beverage | 可口可乐公司 | 2022-06-14 | — | — | CN | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220142216-A1 | Novel Mogrosides and Uses of the Same | THE COCA-COLA COMPANY | 2022-05-12 | — | — | US | disclosed |
| WO-2022056224-A1 | WATER-SOLUBLE FILM FOR PREPARING A BEVERAGE | THE COCA-COLA COMPANY (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | PRKAG1 1642/4885PRKAA2 1849/4885PRKAB1 1634/4885 |
| US-12428662-B2 | Methods for making high intensity sweeteners | OXER1, MAN1B1, GMDS | PRKAG1 1166/4885PRKAA2 2993/4885PRKAB1 1642/4885 |
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | TAS2R40, TAS2R13, TAS2R31 | PRKAG1 1856/4885PRKAA2 3570/4885PRKAB1 1963/4885 |
| US-12557831-B2 | Mogrosides and uses of the same | TAS2R40, TAS2R20, TAS2R10 | PRKAG1 897/4885PRKAA2 3319/4885PRKAB1 1891/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | PRKAG1 1642/4885PRKAA2 1849/4885PRKAB1 1634/4885 |
| US-12495818-B2 | Dihydrochalcones from Balanophora harlandii | TAS2R46, TAS2R20, TAS2R50 | PRKAG1 3281/4885PRKAA2 1638/4885PRKAB1 3083/4885 |
| US-20220142216-A1 | Novel Mogrosides and Uses of the Same | MAG, UGGT1, OGT | PRKAG1 2543/4885PRKAA2 4734/4885PRKAB1 3684/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | PRKAG1 1642/4885PRKAA2 1849/4885PRKAB1 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.